https://pharminent.com/week-in-review/week-in-review-intelligence-brief-may-2-2026/ 2026-05-02T19:15:39Z Pharminent en Week in Review • INTELLIGENCE BRIEF • May 2, 2026 2026-05-02T19:15:35Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-may-1-2026/ 2026-05-01T23:07:12Z Pharminent en Oncology Intelligence Digest • May 1, 2026 2026-05-01T23:07:08Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-may-1-2026/ 2026-05-01T22:41:32Z Pharminent en GLP-1 Competitive Market Digest • Weekly • May 1, 2026 2026-05-01T22:41:29Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-may-1-2026/ 2026-05-01T17:47:21Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • May 1, 2026 2026-05-01T17:47:18Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-1-2026/ 2026-05-01T17:12:11Z Pharminent en Strategic News Watch • May 1, 2026 2026-05-01T17:12:08Z Blog https://pharminent.com/novartis-unveils-north-carolina-api-plant-as-final-piece-of-23b-us-expansion/ 2026-05-01T16:26:58Z Pharminent en Novartis unveils North Carolina API plant as final piece of $23B US expansion 2026-05-01T14:53:11Z Blog https://pharminent.com/amgen-positions-maritide-as-potential-best-monthly-obesity-drug/ 2026-05-01T16:27:01Z Pharminent en Amgen positions MariTide as potential 'best monthly' obesity drug 2026-05-01T12:44:14Z Blog https://pharminent.com/fdas-odac-delivers-one-loss-one-win-for-astrazeneca/ 2026-05-01T16:27:02Z Pharminent en FDA's ODAC delivers one loss, one win for AstraZeneca 2026-05-01T11:19:26Z Blog https://pharminent.com/axsome-receives-fda-approval-for-auvelity-to-treat-alzheimers-agitation/ 2026-05-01T16:27:03Z Pharminent en Axsome receives FDA approval for Auvelity to treat Alzheimer's agitation 2026-05-01T09:55:43Z Blog https://pharminent.com/leo-pharma-to-acquire-gene-therapy-company-replay/ 2026-05-01T16:27:03Z Pharminent en LEO Pharma to acquire gene therapy company Replay 2026-05-01T09:37:44Z Blog https://pharminent.com/eli-lilly-lifts-2026-revenue-guidance-as-q1-marks-dominant-opening/ 2026-05-01T16:27:04Z Pharminent en Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening 2026-05-01T09:32:32Z Blog https://pharminent.com/bms-brings-the-buzz-around-late-stage-readouts-amid-a-so-so-q1/ 2026-05-01T16:27:05Z Pharminent en BMS brings the buzz around late-stage readouts amid a so-so Q1 2026-05-01T09:20:53Z Blog https://pharminent.com/where-gross-to-net-pressure-actually-lives-after-launch/ 2026-05-01T16:27:06Z Pharminent en Where Gross-to-net Pressure Actually Lives After Launch 2026-05-01T04:00:00Z Blog https://pharminent.com/two-biotechs-raise-a-combined-556m-in-latest-spurt-of-ipos/ 2026-05-01T16:27:06Z Pharminent en Two biotechs raise a combined $556M in latest spurt of IPOs 2026-05-01T02:03:00Z Blog